BACKGROUND: Healthcare systems vary among countries, and in many countries, insurance and economic statuses significantly impact the mortality associated with head and neck squamous cell carcinoma (HNSCC). Japan prides itself on its unique healthcare and health insurance system, which provides equal coverage and healthcare access with low individual payments to most citizens. Additionally, citizens in poverty are covered by insurance for the poor (public assistance) and receive medical and other types of assistance. Hence, they have no barriers to healthcare services. This study aimed to determine the impact of health insurance status on mortality in Japanese patients with HNSCC. METHODS: We reviewed 409 patients with HNSCC, using the Kaplan-Meier method to estimate overall survival. The association between insurance status and disease stage at diagnosis was analyzed via logistic regression. Cox and Fine-Gray proportional hazard models were employed to investigate the impact of insurance status on survival. RESULTS: The public assistance and other insurances groups did not significantly differ in clinical stage distribution. The 5-year overall survival, cumulative incidence of HNSCC death, and cumulative incidence of other death rates were 63.3 and 59.1 %, 27.0 and 31.8 %, and 10.3 and 9.7 % for the public assistance and other insurances groups, respectively. The adjusted subdistribution hazard ratio for the association between public assistance and HNSCC death was 0.73 (95 % confidence interval 0.44-1.21). CONCLUSIONS: The demonstrated non-inferiority of public assistance regarding HNSCC-specific mortality indicates the equality of healthcare in Japan, irrespective of the insurance status, and the superiority of the Japanese healthcare system.
BACKGROUND: Healthcare systems vary among countries, and in many countries, insurance and economic statuses significantly impact the mortality associated with head and neck squamous cell carcinoma (HNSCC). Japan prides itself on its unique healthcare and health insurance system, which provides equal coverage and healthcare access with low individual payments to most citizens. Additionally, citizens in poverty are covered by insurance for the poor (public assistance) and receive medical and other types of assistance. Hence, they have no barriers to healthcare services. This study aimed to determine the impact of health insurance status on mortality in Japanese patients with HNSCC. METHODS: We reviewed 409 patients with HNSCC, using the Kaplan-Meier method to estimate overall survival. The association between insurance status and disease stage at diagnosis was analyzed via logistic regression. Cox and Fine-Gray proportional hazard models were employed to investigate the impact of insurance status on survival. RESULTS: The public assistance and other insurances groups did not significantly differ in clinical stage distribution. The 5-year overall survival, cumulative incidence of HNSCC death, and cumulative incidence of other death rates were 63.3 and 59.1 %, 27.0 and 31.8 %, and 10.3 and 9.7 % for the public assistance and other insurances groups, respectively. The adjusted subdistribution hazard ratio for the association between public assistance and HNSCC death was 0.73 (95 % confidence interval 0.44-1.21). CONCLUSIONS: The demonstrated non-inferiority of public assistance regarding HNSCC-specific mortality indicates the equality of healthcare in Japan, irrespective of the insurance status, and the superiority of the Japanese healthcare system.
Entities:
Keywords:
Head and neck cancer; Health insurance; Income
Authors: K Uchimura; J Ngamvithayapong-Yanai; L Kawatsu; A Ohkado; T Yoshiyama; K Ito; N Ishikawa Journal: Int J Tuberc Lung Dis Date: 2015-03 Impact factor: 2.373
Authors: David I Conway; Darren R Brenner; Alex D McMahon; Lorna M D Macpherson; Antonio Agudo; Wolfgang Ahrens; Cristina Bosetti; Hermann Brenner; Xavier Castellsague; Chu Chen; Maria Paula Curado; Otávio A Curioni; Luigino Dal Maso; Alexander W Daudt; José F de Gois Filho; Gypsyamber D'Souza; Valeria Edefonti; Eleonora Fabianova; Leticia Fernandez; Silvia Franceschi; Maura Gillison; Richard B Hayes; Claire M Healy; Rolando Herrero; Ivana Holcatova; Vijayvel Jayaprakash; Karl Kelsey; Kristina Kjaerheim; Sergio Koifman; Carlo La Vecchia; Pagona Lagiou; Philip Lazarus; Fabio Levi; Jolanta Lissowska; Daniele Luce; Tatiana V Macfarlane; Dana Mates; Elena Matos; Michael McClean; Ana M Menezes; Gwenn Menvielle; Franco Merletti; Hal Morgenstern; Kirsten Moysich; Heiko Müller; Joshua Muscat; Andrew F Olshan; Mark P Purdue; Heribert Ramroth; Lorenzo Richiardi; Peter Rudnai; Stimson Schantz; Stephen M Schwartz; Oxana Shangina; Lorenzo Simonato; Elaine Smith; Isabelle Stucker; Erich M Sturgis; Neonila Szeszenia-Dabrowska; Renato Talamini; Peter Thomson; Thomas L Vaughan; Qingyi Wei; Deborah M Winn; Victor Wunsch-Filho; Guo-Pei Yu; Zuo-Feng Zhang; Tongzhang Zheng; Ariana Znaor; Paolo Boffetta; Shu-Chun Chuang; Marianoosh Ghodrat; Yuan-Chin Amy Lee; Mia Hashibe; Paul Brennan Journal: Int J Cancer Date: 2014-08-23 Impact factor: 7.396
Authors: Joseph Kwok; Scott M Langevin; Athanassios Argiris; Jennifer R Grandis; William E Gooding; Emanuela Taioli Journal: Cancer Date: 2010-01-15 Impact factor: 6.860
Authors: D I Conway; P A McKinney; A D McMahon; W Ahrens; N Schmeisser; S Benhamou; C Bouchardy; G J Macfarlane; T V Macfarlane; P Lagiou; P Minaki; V Bencko; I Holcátová; F Merletti; L Richiardi; K Kjaerheim; A Agudo; X Castellsague; R Talamini; L Barzan; C Canova; L Simonato; R J Lowry; A Znaor; C M Healy; B E McCartan; M Marron; M Hashibe; P Brennan Journal: Eur J Cancer Date: 2009-10-24 Impact factor: 9.162